{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007426","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.799684+00:00","generated_at":"2026-06-14T10:55:58.998274+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF","bullets":["Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.","No FDA-approved treatments exist for PH-HFpEF, affecting >1.6M North Americans, projected >2M by 2030.","Phase 2 HELP study showed levosimendan improved 6-minute walk by 29 meters (p=0.03) vs placebo.","Tenax intends to initiate Phase 3 trial of oral formulation in 2023; FDA agreed 6-minute walk test as primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007426","json":"https://secwatch.observer/filing/0001654954-23-007426.json","markdown":"https://secwatch.observer/filing/0001654954-23-007426.md","text":"https://secwatch.observer/filing/0001654954-23-007426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423007426/0001654954-23-007426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423007426/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:55:58.998274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}